Markets:

Overview

News

Currencies

International

Treasuries

MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

14.39 +3.10 (+27.46%)

Streaming Delayed Price Updated: 1:20 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about MoonLake Immunotherapeutics - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 Next >

These stocks are gapping in today's session ↗

Today 10:30 EST

Via Chartmill

Why Did MLTX Stock Jump 45% In Pre-Market Today? ↗

Today 9:11 EST

The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder.

Via Stocktwits

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

Today 8:30 EST

Via Chartmill

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 28, 2025

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Via The Motley Fool

Topics Lawsuit Regulatory Compliance

MoonLake Therapeutics Stock Sparks Retail Frenzy Ahead Of New York Summit — Traders See 'Nonstop Catalysts' Through 2026 ↗

November 13, 2025

Via Stocktwits

MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades ↗

September 29, 2025

Via Stocktwits

MoonLake Immunotherapeutics Stock Draws Buzz After Skin Drug’s Phase 3 Trial Data — Retail Speculates Buyout, Bigger Gains ↗

September 28, 2025

Via Stocktwits

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 27, 2025

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Via The Motley Fool

Topics Lawsuit Regulatory Compliance

5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗

November 18, 2025

A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next.

Via The Motley Fool

The Best AI for Picking Stocks, Ranked by Performance ↗

October 22, 2025

AI can pick stocks, but that doesn't mean it will do a good job. Here's a look at how the choices made by 7 leading AIs performed over a 90-day time period.

Via MarketBeat

Topics Artificial Intelligence ETFs

Which stocks have an unusual volume on Monday? ↗

October 06, 2025

Volume analysis on 2025-10-06: stocks with an unusual volume in today's session.

Via Chartmill

Top 3 Health Care Stocks That Are Preparing To Pump In Q4 ↗

October 06, 2025

Via Benzinga

Unusual volume stocks are being observed in Friday's session. ↗

October 03, 2025

In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.

Via Chartmill

Unusual volume stocks are being observed in Thursday's session. ↗

October 02, 2025

In today's session, these stocks are experiencing unusual volume.

Via Chartmill

Unusual volume stocks are being observed in Wednesday's session. ↗

October 01, 2025

Discover the stocks with unexpected trading volume in today's session on the US markets.

Via Chartmill

MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside ↗

September 30, 2025

Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares.

Via Stocktwits

Wall Street Lights Up as Cannabis Stocks Blaze Higher, Biotech Melts Down ↗

September 30, 2025

U.S. markets kicked off the week quietly, but certain stocks were anything but dull. Cannabis names surged after a Trump-endorsed CBD video went viral, while biotech firm MoonLake was crushed by...

Via Chartmill

Topics Cannabis

Wolfspeed, Tilray, Robinhood, Etsy, And Moonlake Immunotherapeutics: Why These 5 Stocks Are On Investors' Radars Today ↗

September 29, 2025

U.S. stocks advanced today, with the Nasdaq climbing about 107 points, or 0.48%, to 22,591.15. The S&P 500 added 0.26% to close at 6,661.21, while the Dow Jones Industrial Average edged up 0.15% to...

Via Benzinga

Topics Stocks

Crude Oil Falls Sharply; Carnival Posts Upbeat Earnings ↗

September 29, 2025

U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday. The Dow traded down 0.12% to 46,190.92 while the NASDAQ rose 0.40% to 22,574.89. The S&P 500...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 29, 2025

Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44....

Via Benzinga

Nasdaq Jumps 150 Points; US Pending Home Sales Rise ↗

September 29, 2025

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 150 points on Monday. Following the market opening Monday, the Dow traded up 0.19% to 46,333.68 while the NASDAQ rose...

Via Benzinga

Topics Stocks

MoonLake Crashes 89% On Mixed Results For Skin Disease Treatment ↗

September 29, 2025

MoonLake Immunotherapeutics stock crashed Monday after the company posted mixed results for its skin disease drug.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 29, 2025

Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.

Via Benzinga

Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

September 29, 2025

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1...

Via Benzinga

Topics Stocks

This Electronic Arts Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗

September 29, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...

Via Benzinga

Why Is MoonLake Immunotherapeutics Stock Crashing Premarket? ↗

September 29, 2025

RBC Capital downgraded the stock, calling the results a “near-miss” statistically and warning that the drug’s effect size looked uncompetitive.

Via Stocktwits

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket ↗

September 29, 2025

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its...

Via Benzinga

2 Small-Cap Biotech Stocks Well Positioned for a Breakout ↗

August 27, 2025

Clinical trial results expected in the weeks ahead could push shares of these small-cap drugmakers through the roof.

Via The Motley Fool

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery ↗

June 13, 2025

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial.

Via Benzinga

Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta ↗

June 06, 2025

Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates.

Via Benzinga

Topics Bankruptcy

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.